Shoulder Innovations, Inc.

NYSE:SI

Medical - Specialties

Healthcare
$20.65 -0.72%

-$0.13 today

Market cap
$432.04M
Beta
-1.07
P/E (TTM)
-8.4
EPS (TTM)
-$2.13
52W Low $10.92High $19.79

Volume 0.09M

Average 0.10M

SI Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Shoulder Innovations, Inc.NYSE: SI

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 77.7%

Gross margin was 77.7% in Q1 FY2026, up 7.4 pp from a year earlier. On a trailing-twelve-month basis it was 75.5%, up 0.4 pp year over year.

Context

  • Gross margin widened in 0 of the last 2 fiscal years.
  • FY2025 was the lowest level in the 3 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
77.7%+1.0 pp QoQ
Last fiscal yearDec 2025
76.5%-0.5 pp YoY
LTMMar 2026
75.5%+0.4 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+7.4 pp——
1 year-0.5 pp——
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
76.5%
Year-over-year change
-0.5pp

Gross Margin vs competitors

How SI compares with its peers on the latest reported figures

  • SI's LTM Mar 2026 gross margin of 75.5% is the 4th highest of the 8 companies compared; the peer median is 59.7%.
  • Its year-over-year change of +0.4 pp is the 4th highest of 8, against a peer median of -0.9 pp.
SI Competitors Peer median
Gross Margin for SI and competitors
Company Period LTM level YoY 3-year change
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 202698.3% -1.7 pp-7.0 pp
ASMBAssembly Biosciences, Inc.LTM Mar 202677.2% +110.0 pp—
SNWVSANUWAVE Health, Inc.LTM Mar 202675.7% -0.9 pp+3.0 pp
SIShoulder Innovations, Inc.LTM Mar 202675.5% +0.4 pp—
MDXHMDxHealth S.A.FY202559.7% -1.5 pp+7.9 pp
INGNInogen, Inc.LTM Mar 202648.7% +2.6 pp+6.9 pp
OMOutset Medical, Inc.LTM Mar 202640.6% +4.7 pp+23.7 pp
NNOXNano-X Imaging Ltd.LTM Dec 2025-98.2% -3.3 pp-18.0 pp
EPRXEupraxia Pharmaceuticals Inc.FY2025— ——
NAUTNautilus Biotechnology, Inc.FY2025— ——
AARDAardvark Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding SI) 59.7%-0.9 pp+4.9 pp

Competitors are the stored peer set for SI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue19.27M31.62M47.32M
Cost of Revenue4M7.28M11.12M
Gross Profit15.27M24.34M36.2M
Gross Margin79.2%77.0%76.5%
Research & Development3.02M4.49M7.73M
Selling, General & Admin23.11M34.51M54.77M
Operating Expenses26.13M38.99M62.5M
Depreciation & Amortization1.64M2.2M3.21M
EBITDA(10.25M)(12.11M)(37.08M)
EBITDA Margin-53.2%-38.3%-78.4%
Operating Income(10.86M)(14.65M)(26.3M)
Operating Margin-56.4%-46.3%-55.6%
Interest Income000
Interest Expense761K1.32M70K
Other Income / Expenses(1.79M)(966K)(14.06M)
Income Before Tax(12.66M)(15.62M)(40.36M)
Pre-Tax Margin-65.7%-49.4%-85.3%
Income Tax Expense000
Net Income(12.66M)(15.62M)(40.36M)
Net Margin-65.7%-49.4%-85.3%
EPS (Basic)(0.63)(0.77)(1.96)
EPS (Diluted)(0.63)(0.77)(1.96)
Weighted Avg Shares19.92M19.92M20.63M
Weighted Avg Shares (Diluted)19.92M19.92M20.63M

Shoulder Innovations, Inc.

NYSE:SI

Intrinsic Alpha fair value

Locked

Current Price

$20.65

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.